曼恩凱德生物醫療 MNKD 深 滬
已收盤 07-25 16:00:00 美东时间
4.06
-0.020
-0.49%
華盛通- 最 高4.13
- 今 開4.10
- 成交量 243.55万股
- 最 低 4.02
- 昨 收 4.08
- 總市值 12.34亿
- 52周最高 7.63
- 市盈率 靜 41.77
- 換手率 0.80%
- 52周最低 3.51
- 委 比 -47.38%
- 總股本 3.04亿
- 歷史最高 57.40
- 量 比 1.00
- 振 幅 2.70%
- 歷史最低 0.666
- 每 手 1
- 風險率 1.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RBC Capital Maintains Outperform on MannKind, Lowers Price Target to $8
RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $10 to $8.
07-23 21:05
HC Wainwright & Co. Assumes MannKind at Buy, Announces Price Target of $9
HC Wainwright & Co. analyst Brandon Folkes assumes MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $9.
07-16 19:24
CEL-SCI announces pricing of $5.7 million offering
CEL-SCI (NYSE:CVM) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share,...
07-12 03:04
Nektar Therapeutics surge continues as stock up another 25%
Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up anot...
06-26 02:14
Gene editors steady despite latest leadership shake-up at FDA
Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following...
06-20 20:39
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST
Ocugen (NASDAQ:OCGN) said on Monday that the U.S. FDA has cleared the company to initiate a phase 2/3 confirmatory trial of its modifier gene therapy, OCU410ST, to treat Stargardt disease, an eye diso...
06-16 21:38
Top 3 Health Care Stocks That May Rocket Higher This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
06-11 19:01
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
MannKind Corporation will showcase inhaled insulin at the American Diabetes Association’s 85th Scientific Sessions in Chicago from June 20-23. Dr. Michael J. Haller will present results from the Phase 3 INHALE-1 study of Afrezza in children and adolescents. Additional presentations will cover patient-reported outcomes and the efficacy of Afrezza in adults with T2DM. MannKind will also host a booth for scientific discussions. The company expects t...
06-09 20:05
Ocugen signs license deal with Korean company for gene therapy
Ocugen (NASDAQ:OCGN) said on Thursday that it has signed a term sheet to negotiate a licensing deal with a pharmaceutical company in Korea. This agreement will grant exclusive Korean rights to OCU400...
06-05 21:32
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
MannKind Corporation partners with NTT INDYCAR SERIES driver Conor Daly, the only known U.S. professional racing driver with Type 1 diabetes, to inspire Detroit youth during the Chevrolet Detroit Grand Prix week. Daly, diagnosed at age 14, will share his story of living with T1D while pursuing a successful racing career, including karting tips and a go-kart race to find the Fastest 6. He competes for Juncos Hollinger Racing in the Chevrolet Detro...
05-27 13:15
